{"id":509,"date":"2025-01-23T11:46:21","date_gmt":"2025-01-23T11:46:21","guid":{"rendered":"https:\/\/perfusfind.com\/ic\/?p=509"},"modified":"2025-01-23T11:46:21","modified_gmt":"2025-01-23T11:46:21","slug":"use-of-antimicrobials-for-bloodstream-infections-in-the-intensive-care-unit-a-clinically-oriented-review","status":"publish","type":"post","link":"https:\/\/perfusfind.com\/ic\/index.php\/2025\/01\/23\/use-of-antimicrobials-for-bloodstream-infections-in-the-intensive-care-unit-a-clinically-oriented-review\/","title":{"rendered":"Use of Antimicrobials for Bloodstream Infections in the Intensive Care Unit, a Clinically Oriented Review"},"content":{"rendered":"

Abstract<\/h2>\n
Bloodstream infections (BSIs) in critically ill patients are associated with significant mortality. For patients with septic shock, antibiotics should be administered within the hour. Probabilistic treatment should be targeted to the most likely pathogens, considering the source and risk factors for bacterial resistance including local epidemiology. Source control is a critical component of the management. Sending blood cultures (BCs) and other specimens before antibiotic administration, without delaying them, is key to microbiological diagnosis and subsequent opportunities for antimicrobial stewardship. Molecular rapid diagnostic testing may provide faster identification of pathogens and specific resistance patterns from the initial positive BC. Results allow for antibiotic optimisation, targeting the causative pathogen with escalation or de-escalation as required. Through this clinically oriented narrative review, we provide expert commentary for empirical and targeted antibiotic choice, including a review of the evidence and recommendations for the treatments of extended-spectrum \u03b2-lactamase-producing, AmpC-hyperproducing and carbapenem-resistant Enterobacterales; carbapenem-resistant\u00a0Acinetobacter baumannii;<\/span>\u00a0and\u00a0Staphylococcus aureus<\/span>. In order to improve clinical outcomes, dosing recommendations and pharmacokinetics\/pharmacodynamics specific to ICU patients must be followed, alongside therapeutic drug monitoring.<\/div>\n
\n

Key Points<\/strong><\/p><\/blockquote>\n

    \n
  1. Prompt Therapy<\/strong>: Antibiotics should be administered within an hour of sepsis recognition to reduce mortality, with delays linked to increased risk of death.<\/li>\n
  2. Blood Cultures<\/strong>: Timely blood sampling before starting antimicrobials is crucial for accurate pathogen identification and treatment optimization.<\/li>\n
  3. Rapid Diagnostics<\/strong>: Molecular rapid diagnostic testing (mRDT) accelerates pathogen identification and susceptibility profiling, aiding timely therapy adjustments.<\/li>\n
  4. Empirical Treatment<\/strong>: Initial broad-spectrum regimens should target likely pathogens and risk factors for multidrug resistance, with a plan for de-escalation based on culture results.<\/li>\n
  5. De-escalation<\/strong>: Streamlining therapy to narrow-spectrum agents reduces resistance risks and improves patient outcomes.<\/li>\n
  6. Key Pathogens<\/strong>: Management of resistant organisms like ESBL-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and MRSA is detailed, including novel antimicrobial combinations.<\/li>\n
  7. Source Control<\/strong>: Surgical or percutaneous interventions to remove infection sources are critical for successful BSI management.<\/li>\n
  8. Dosing Strategies<\/strong>: ICU-specific pharmacokinetics necessitate adjusted dosing regimens to ensure therapeutic levels and minimize toxicity.<\/li>\n
  9. Shorter Treatment Durations<\/strong>: Evidence supports 7-day regimens for uncomplicated Gram-negative BSIs, balancing efficacy and reduced adverse effects.<\/li>\n
  10. Stewardship Programs<\/strong>: Integration of antimicrobial stewardship in ICU practices optimizes therapy duration, reduces overuse, and curtails resistance development.<\/li>\n<\/ol>\n

    ACCESS FULL ARTICLE HERE<\/strong><\/a><\/p>\n